Study on efficacy and safety of improved male urinary incontinence harness

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300072254

Enrollment

Unknown

Registered

2023-06-07

Start date

2023-06-01

Completion date

Unknown

Last updated

2023-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stress Urinary Incontinence

Interventions

The control group:Pelvic floor muscle training+M receptor blocker

The experimental group:Improved male urinary incontinence harness

Eligibility

Sex/Gender

Male

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) The age ranges from 18 years (including 18 years) to 80 years (including 80 years). (2) 1 year after radical prostatectomy (3) There is a de novo stress urinary incontinence after prostatectomy, and the symptoms persisit. (4) The main organs have good function and The oagulation function is normal. (5) Life expectancy (>5 years); (6) Subjects signed informed consent before enrollment to participate in the study and abide by the research procedure.

Exclusion criteria

Exclusion criteria: (1) A history of other malignant tumors; (2) Uncontrolled local or systemic infection; (3) Uncontrollable systemic hemorrhagic diseases, severe hypercoagulability, severe coagulation disorders or using drugs that affect coagulation function; (4) Deep venous thrombosis (5)Has received other prostate surgery, such as TURP or Holep, or have symptom of SUI before surgery; (6) The important organs are in the acute stage of disease or with parasitic diseases. (7) Human immunodeficiency virus (HIV) positive patients, patients with immunodeficiency disorders, patients with combined immunodeficiency disorders, organ transplants, patients with autoimmune diseases requiring immunosuppressive or steroid therapy, or other severe immunosuppressive conditions; (8) Any mental or cognitive impairment, emotional instability, may limit their understanding of informed consent, or execution and compliance of research; (9) Researchers do not think he is suitable to participate in this experiment.

Design outcomes

Primary

Measure	Time frame
Number of pads used daily by patients;	—

Secondary

Measure	Time frame
Score of ICI-Q-SF;Urinary routine;	—

Countries

China

Contacts

Public ContactJianwei Lv

Gongli Hospital, Shanghai

ljwass@126.com+86 138 1669 4688

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026